Cargando…
Addition of chemotherapy to nivolumab after PD-1 inhibitor failure as bridge to allogeneic stem cell transplantation in classical Hodgkin’s lymphoma: report on three cases and literature review
The poor prognosis of refractory or relapsed (R/R) classical Hodgkin’s lymphoma (cHL) after autologous stem cell transplantation has improved greatly due to the introduction of brentuximab vedotin and PD-1 inhibitors. However, the duration of response achieved with these novel agents is too short. T...
Autores principales: | Romero, Samuel, Balaguer-Roselló, Aitana, Montoro, Juan, Beneit, Paola, Martínez, Amelia, Ruiz, Cristina, Andreu, Rafael, Guerreiro, Manuel, Arnao, Mario, Montava, Alberto, Vicente, Ana I., Jarque, Isidro, Sanz, Jaime |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381419/ https://www.ncbi.nlm.nih.gov/pubmed/34434538 http://dx.doi.org/10.1177/20406207211038181 |
Ejemplares similares
-
The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation
por: Piñana, JoséLuis, et al.
Publicado: (2020) -
Transfusion Burden in Allogeneic Hematopoietic Stem Cell Transplantation over Time: Experience from a Single Institution
por: Solves, Pilar, et al.
Publicado: (2023) -
Common seasonal respiratory virus infections in allogeneic stem cell transplant recipients during the SARS-COV-2 pandemic
por: De la Puerta, Rosalía, et al.
Publicado: (2021) -
The effect of timing on community acquired respiratory virus infection mortality during the first year after allogeneic hematopoietic stem cell transplantation: a prospective epidemiological survey
por: Piñana, José Luis, et al.
Publicado: (2019) -
FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma
por: Kasamon, Yvette L., et al.
Publicado: (2017)